You can buy or sell DPLO and other stocks, options, ETFs, and crypto commission-free!
Diplomat Pharmacy, Inc. engages in the provision of specialty pharmacy and infusion services. It operates through the Specialty and Pharmacy Benefit Management segments. Read More The Specialty segment offers a range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost specialty drugs, and a wide range of applications. The Pharmacy Benefit Management segment provides services designed to help the customers reduce the cost and manage the complexity of their prescription drug programs. The company was founded by Dale Hagerman and Philip Hagerman in 1975 and is headquartered in Flint, MI.
52 Week High
52 Week Low
Current Trend: Diplomat Pharmacy (NYSE: DPLO)
Diplomat Pharmacy is in the healthcare sector and is in the drug manufacturers industry. The company CEO is Brian T. Griffin. Diplomat Pharmacy Inc is a provider of pharmaceutical drugs in the United States. It generates its revenue through the sale of prescriptions drugs for serious diseases such as hepatitis and multiple sclerosis. Previous Intraday Trading Performance: The DPLO stock showed a previous change of 2.79% with an open at 5.67 and a close of 5.90. It reached an intraday high of 6.06 and a lo...
Seeking AlphaMay 7
Diplomat Pharmacy, Inc. (DPLO) CEO Brian Griffin on Q1 2019 Results - Earnings Call Transcript
Diplomat Pharmacy, Inc. (NYSE:DPLO) Q1 2019 Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Terri Anne Powers - Vice President, Investor Relations Brian Griffin - Chairman & Chief Executive Officer Dan Davison - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Steven Valiquette - Barclays A.J. Rice - Crédit Suisse Jon Kaufman - William Blair David Larsen - Leerink Eric Coldwell - Baird Ricky Goldwasser - Morgan Stanley Charles Rhyee - Cowen John Ra...
Expected Aug 5, After Hours